NZ733351A - Combinations of modalities for the treatment of diabetes - Google Patents
Combinations of modalities for the treatment of diabetesInfo
- Publication number
- NZ733351A NZ733351A NZ733351A NZ73335113A NZ733351A NZ 733351 A NZ733351 A NZ 733351A NZ 733351 A NZ733351 A NZ 733351A NZ 73335113 A NZ73335113 A NZ 73335113A NZ 733351 A NZ733351 A NZ 733351A
- Authority
- NZ
- New Zealand
- Prior art keywords
- diabetes
- modalities
- combinations
- treatment
- administering
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 abstract 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 101000825079 Homo sapiens Transcription factor SOX-13 Proteins 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 230000020385 T cell costimulation Effects 0.000 abstract 1
- 102100022435 Transcription factor SOX-13 Human genes 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule and a B-chain insulin vaccine. Pharmaceutical compositions are also provided herewith.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/534,571 US8735359B2 (en) | 2012-05-24 | 2012-06-27 | Combinations of modalities for the treatment of diabetes |
| NZ70364113 | 2013-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ733351A true NZ733351A (en) | 2020-01-31 |
Family
ID=69184841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ733351A NZ733351A (en) | 2012-06-27 | 2013-06-27 | Combinations of modalities for the treatment of diabetes |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ733351A (en) |
-
2013
- 2013-06-27 NZ NZ733351A patent/NZ733351A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016502390A1 (en) | Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist | |
| MX2018015393A (en) | Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof. | |
| WO2018083087A3 (en) | Binding proteins | |
| PH12016502391A1 (en) | Composition for treating diabetes, comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate | |
| FI3389699T3 (en) | Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof | |
| MX2017008487A (en) | Nanoparticle compositions and methods for immunotherapy. | |
| MX2017010159A (en) | Vector co-expressing vaccine and costimulatory molecules. | |
| MX2017016502A (en) | Antibodies to cd40 with enhanced agonist activity. | |
| NZ730763A (en) | Methods of treating a tauopathy | |
| WO2016014565A3 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| MX360295B (en) | Ox40l fusion proteins and uses thereof. | |
| MX2017016253A (en) | Antibodies to cd40. | |
| PH12014501351A1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
| NZ590343A (en) | Compositions monovalent for cd28 binding and methods of use | |
| WO2015106269A8 (en) | Rapid action insulin formulations and pharmaceutical delivery systems | |
| BR112016029123A2 (en) | lymphoma treatment | |
| EP3072506A4 (en) | Carrier for drug delivery and conjugate, composition containing same, and method for administering same | |
| MX2018010672A (en) | Antibodies to cd40 with enhanced agonist activity. | |
| PE20170142A1 (en) | FUSION PROTEIN INHIBITING ANGIOGENESIS OR GROWTH AND USE OF THE SAME | |
| MX2019014375A (en) | Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof. | |
| WO2017041001A3 (en) | Insulin immunoglobulin fusion proteins | |
| NZ721015A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| MX2015017959A (en) | Compositions and methods for immunotherapy. | |
| MX2016016210A (en) | Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies. | |
| EA201370162A1 (en) | NEW PHARMACEUTICAL COMPOSITION WITH WEAK SIDE EFFECT, INCLUDING ANTI-TURBINE PREPARATIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JUN 2021 BY CPA GLOBAL Effective date: 20201119 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JUN 2022 BY CPA GLOBAL Effective date: 20210513 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JUN 2023 BY CPA GLOBAL Effective date: 20221020 |
|
| LAPS | Patent lapsed |